Top

18-08-2016 | Chronic myeloid leukemia | Book chapter | Article

7. Epidemiology of Chronic Myeloid Leukemia

Authors: Martin Höglund, MD, PhD, Fredrik Sandin, Bengt Simonsson

Publisher: Springer International Publishing

Abstract

National and regional population-based registries are, provided diagnostic accuracy and full coverage of the target population, indispensible tools for epidemiological research. CML registries with a more comprehensive reporting may also provide complementary data on treatment outcome to those obtained from clinical trials. Reports from several European CML registries consistently show a crude annual incidence of 0.7–1.3/100,000, median age at diagnosis of 56–60 years and a male/female ratio of 1.2–1.7. The incidence of CML has been stable over time. Worldwide, variations in reported incidence of CML may be due to methodological issues, but a true difference between different geographical areas and/or ethnical subgroups cannot be excluded. The prevalence of CML is less well known but has been estimated to 10–12/100,000 inhabitants with a steady increase due to the dramatic improvement in survival of these patients. In recent population-based studies, CML patients have an overall survival that is comparable to that shown in large clinical trials, though relative survival in patients >70 years is still decreased. The importance of socioeconomic factors and health-care setting for outcome, a possible increased risk of secondary cancer in CML and possible long-term adverse off-target effects related to the use of tyrosine kinase inhibitors, are areas of ongoing epidemiological research.

Barlow L, Westergren K, Holmberg L, Talback M (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48(1):27–33. doi:10.1080/02841860802247664 CrossRefPubMed

Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Loffler H, Pralle H, Queisser W, Hehlmann R (2005) Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia Off J Leuk Soc Am Leuk Res Fund UK 19(6):984–989. doi:10.1038/sj.leu.2403756 CrossRef

Berglund A, Holmberg L, Tishelman C, Wagenius G, Eaker S, Lambe M (2010) Social inequalities in non-small cell lung cancer management and survival: a population-based study in central Sweden. Thorax 65(4):327–333. doi:10.1136/thx.2009.125914 CrossRefPubMed

Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R (2009) The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer 9:252. doi:10.1186/1471-2407-9-252 CrossRefPubMedPubMedCentral

Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J, Andersson T, Hoglund M, Richter J, Landgren O, Kristinsson SY, Dickman PW (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29(18):2514–2520. doi:10.1200/JCO.2011.34.7146 CrossRefPubMedPubMedCentral

Bjorkholm M, Kristinsson SY, Landgren O, Goldin LR (2013) No familial aggregation in chronic myeloid leukemia. Blood 122(3):460–461. doi:10.1182/blood-2013-05-501312 CrossRefPubMedPubMedCentral

Bjorkholm M, Bower H, Dickman PW, Lambert PC, Höglund M, Andersson TM-L (2016) Temporal trends in chronic myeloid leukemia outcome using the loss in expectation of life: a Swedish population-based study. J Clin Onocl 126(23):2779–2779

Bray F, Parkin DM (2009) Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer 45(5):747–755. doi:10.1016/j.ejca.2008.11.032 CrossRefPubMed

Breccia M, Alimena G (2013) The role of comorbidities in chronic myeloid leukemia. Leuk Res 37(7):729–730. doi:10.1016/j.leukres.2013.04.001 CrossRefPubMed

Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT (2013) Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis. Cancer 119(14):2620–2629. doi:10.1002/cncr.28106 CrossRefPubMed

Carlhed R, Bojestig M, Wallentin L, Lindstrom G, Peterson A, Aberg C, Lindahl B (2006) Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study. Am Heart J 152(6):1175–1181. doi:10.1016/j.ahj.2006.07.028 CrossRefPubMed

Chang CS, Lee K, Yang YH, Lin MT, Hsu CN (2011) Estimation of CML incidence: disagreement between national cancer registry and health claims data system in Taiwan. Leuk Res 35(5):e53–e54. doi:10.1016/j.leukres.2010.12.034 CrossRefPubMed

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed

Chen Y, Wang H, Kantarjian H, Cortes J (2013) Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma 54(7):1411–1417. doi:10.3109/10428194.2012.745525 CrossRefPubMed

Corm S, Micol JB, Leroyer A, Daudignon A, Preudhomme C, Poulain B, Bregman B, Oukessou A, Lai J, Facon T (2008) Kinetic of chronic myeloid leukemia (CML) prevalence in Northern France since the introduction of imatinib. J Clin Oncol 26(15S):7088

Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, Iwaz J, Preudhomme C, Roche-Lestienne C, Facon T, Remontet L (2011) Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Blood 118(16):4331–4337. doi:10.1182/blood-2011-01-330332 CrossRefPubMed

Dahlén T, Edgren G, Höglund M, Lambe M, Björkholm M, Sandin F, Själander A, Richter J, Ohm L, Bäck M, Stenke L (2016) Cardiovascular Events Associated with use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population- Based Cohort Study. Ann Int Med 124(21):3134–3134

de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, Millot F, International BFMGSGCMLC (2014) Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol 167(1):33–47. doi:10.1111/bjh.12977 CrossRefPubMed

Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M (2015) The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. Leuk Res 39(2):177–182. doi:10.1016/j.leukres.2014.11.025 CrossRefPubMed

Faber E, Muzik J, Koza V, Demeckova E, Voglova J, Demitrovicova L, Chudej J, Markuljak I, Cmunt E, Kozak T, Tothova E, Jarosova M, Dusek L, Indrak K (2011) Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000–a report from the population-based CAMELIA Registry. Eur J Haematol 87(2):157–168. doi:10.1111/j.1600-0609.2011.01637.x CrossRefPubMed

Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sorensen HT (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118(25):6515–6520. doi:10.1182/blood-2011-04-348755 CrossRefPubMed

Gale RP, Cozen W, Goodman MT, Wang FF, Bernstein L (2000) Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 24(8):665–669CrossRefPubMed

Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, D’Emilio A, Stagno F, le Coutre P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers J, Valsecchi MG, Kim DW (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103(7):553–561. doi:10.1093/jnci/djr060 CrossRefPubMed

Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117(21):5591–5599. doi:10.1182/blood-2010-12-324228 CrossRefPubMed

Gunnarsson N, Hoglund M, Stenke L, Wallberg Jonsson S, Sandin F, Bjorkholm M, Dreimane A, Lambe M, Markevarn B, Olsson-Stromberg U, Wadenvik H, Richter J, Sjalander A (2015a) Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia. Blood 126(23):1586–1586. doi: 10.1038/leu.2016.59

Gunnarsson N, Stenke L, Hoglund M, Sandin F, Bjorkholm M, Dreimane A, Lambe M, Markevarn B, Olsson-Stromberg U, Richter J, Wadenvik H, Wallvik J, Sjalander A (2015b) Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. Br J Haematol 169(5):683–688. doi:10.1111/bjh.13346 CrossRefPubMed

Harrison SJ, Johnson PR, Holyoake TL (2004) The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scott Med J 49(3):87–90PubMed

Heyssel R, Brill AB, Woodbury LA, Nishimura ET, Ghose T, Hoshino T, Yamasaki M (1960) Leukemia in Hiroshima atomic bomb survivors. Blood 15:313–331PubMed

Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, Hehlmann R (2015) The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 29(6):1336–1343. doi:10.1038/leu.2015.73 CrossRefPubMed

Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M, Dreimane A, Ekblom M, Lehmann S, Ljungman P, Malm C, Markevarn B, Myhr-Eriksson K, Ohm L, Olsson-Stromberg U, Sjalander A, Wadenvik H, Simonsson B, Stenke L, Richter J (2013) Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 122(7):1284–1292. doi:10.1182/blood-2013-04-495598 CrossRefPubMedPubMedCentral

Hoglund M, Sandin F, Simonsson B (2015) Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 94(Suppl 2):S241–S247. doi:10.1007/s00277-015-2314-2 CrossRefPubMed

Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12):3123–3127. doi:10.1002/cncr.26679 CrossRefPubMedPubMedCentral

Juliusson G, Lazarevic V, Horstedt AS, Hagberg O, Hoglund M (2012) Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 119(17):3890–3899. doi:10.1182/blood-2011-12-379008 CrossRefPubMedPubMedCentral

Kantarjian HM, Fojo T, Mathisen M, Zwelling LA (2013) Cancer drugs in the United States: Justum Pretium–the just price. J Clin Oncol 31(28):3600–3604. doi:10.1200/JCO.2013.49.1845 CrossRefPubMedPubMedCentral

Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, Irving I, Jootar S, Goh HG, Koh LP, Li W, Naoe T, Ng SC, Purushotaman V, Reksodiputro H, Shih LY, Tang JL, Tojo A, Wang J, Wong R (2010) Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res 34(11):1459–1471. doi:10.1016/j.leukres.2010.03.033 CrossRefPubMed

Kurtovic-Kozaric A, Hasic A, Radich JP, Bijedic V, Nefic H, Eminovic I, Kurtovic S, Colakovic F, Kozaric M, Vranic S, Bovan NS (2015) The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients. Br J Haematol. doi:10.1111/bjh.13843 PubMed

Lauseker M, Hasford J, Pfirrmann M, Hehlmann R, German CMLSG (2014) The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood 123(16):2494–2496. doi:10.1182/blood-2013-11-539742 CrossRefPubMed

Matasar MJ, Ritchie EK, Consedine N, Magai C, Neugut AI (2006) Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites. Leuk Lymphoma 47(11):2365–2370. doi:10.1080/10428190600799888 CrossRefPubMed

Maynadie M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, Bailly F, Favre B, Caillot D, Petrella T, Flesch M, Carli PM (2011) Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d’Or (Burgundy, France). Haematologica 96(1):55–61. doi:10.3324/haematol.2010.026252 CrossRefPubMed

McQuilten ZK, Wood EM, Polizzotto MN, Campbell LJ, Wall M, Curtis DJ, Farrugia H, McNeil JJ, Sundararajan V (2014) Underestimation of myelodysplastic syndrome incidence by cancer registries: results from a population-based data linkage study. Cancer 120(11):1686–1694. doi:10.1002/cncr.28641 CrossRefPubMed

Mohammadi M, Cao Y, Glimelius I, Bottai M, Eloranta S, Smedby KE (2015) The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma – a Swedish population-based study. BMC Cancer 15:850. doi:10.1186/s12885-015-1857-x CrossRefPubMedPubMedCentral

Musselman JR, Blair CK, Cerhan JR, Nguyen P, Hirsch B, Ross JA (2013) Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation. Cancer Epidemiol 37(4):410–6

Ohm L, Lundqvist A, Dickman P, Hoglund M, Persson U, Stenke L, Steen Carlsson K, Bjorkholm M (2014) Real-world cost-effectiveness in chronic myeloid leukaemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma :1–16. doi:10.3109/10428194.2014.953141

Osca-Gelis G, Puig-Vives M, Saez M, Gallardo D, Lloveras N, Marcos-Gragera R (2013) Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain. Haematologica 98(8):e95–e97. doi:10.3324/haematol.2013.084061 CrossRefPubMedPubMedCentral

Parkin DM, Bray F (2009) Evaluation of data quality in the cancer registry: principles and methods Part II. Completeness Eur J Cancer 45(5):756–764. doi:10.1016/j.ejca.2008.11.033 CrossRefPubMed

Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, Hehlmann R, Simonsson B (2015) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. doi:10.1038/leu.2015.261 PubMedCentral

Proetel U, Pletsch N, Lauseker M, Muller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Muller L, Hanel M, Link H, Hertenstein B, Pfirrman M, Hochhaus A, Hasford J, Hehlmann R, Saussele S, German Chronic Myeloid Leukemia Study G, Schweizerische Arbeitsgemeinschaft fur Klinische K (2014) Older patients with chronic myeloid leukemia (>/=65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol 93(7):1167–1176. doi:10.1007/s00277-014-2041-0

Pulte D, Gondos A, Redaniel MT, Brenner H (2011) Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist 16(5):663–671. doi:10.1634/theoncologist.2010-0393 CrossRefPubMedPubMedCentral

Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, Gale RP, Sachs RK (2014) Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys 53(1):55–63. doi:10.1007/s00411-013-0507-4 CrossRefPubMed

Rebora P, Czene K, Antolini L, Gambacorti Passerini C, Reilly M, Valsecchi MG (2010) Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study. Am J Epidemiol 172(9):1028–1033. doi:10.1093/aje/kwq262 CrossRefPubMed

Rego MN, Metze K, Lorand-Metze I (2015) Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil. Clinics (Sao Paulo) 70(5):322–325. doi:10.6061/clinics/2015(05)03 CrossRef

Rohrbacher M, Hasford J (2009) Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 22(3):295–302. doi:10.1016/j.beha.2009.07.007 CrossRefPubMed

Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Muller MC, Hasford J, Heimpel H, Hehlmann R (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23(3):602–604. doi:10.1038/leu.2008.245 CrossRefPubMed

SEER (2015) SEER. Cancer Statistics Review 1975-2012. http://seer.cancer.gov

Shah BK, Ghimire KB (2013) Chronic myeloid leukemia survival in older population in the United States. Leuk Lymphoma. doi:10.3109/10428194.2013.775435 PubMedCentral

Smith A, Roman E, Howell D, Jones R, Patmore R, Jack A, Haematological Malignancy Research N (2010) The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 148(5):739–753. doi:10.1111/j.1365-2141.2009.08010.x CrossRefPubMed

Smith AG, Painter D, Howell DA, Evans P, Smith G, Patmore R, Jack A, Roman E (2014) Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open 4(1), e004266. doi:10.1136/bmjopen-2013-004266 CrossRefPubMedPubMedCentral

Socialstyrelsen (2015) Cancer incidence in Sweden 2014. https://www.socialstyrelsen.se/english

Storm HH, Michelsen EV, Clemmensen IH, Pihl J (1997) The Danish Cancer Registry–history, content, quality and use. Dan Med Bull 44(5):535–539PubMed

Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126(1):42–9

Verma D, Kantarjian H, Strom SS, Rios MB, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, O’Brien S, Cortes J (2011) Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 118(16):4353–4358. doi:10.1182/blood-2011-06-362889 CrossRefPubMedPubMedCentral

Visser O, Trama A, Maynadie M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC, Group RW (2012) Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 48(17):3257–3266. doi:10.1016/j.ejca.2012.05.024

Voglova J, Muzik J, Faber E, Zackova D, Klamova H, Steinerova K, Michalovicova Z, Demitrovicova L, Cmunt E, Novakova L, Tothova E, Belohlavkova P, Mayer J, Indrak K (2011) Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma 58(3):256–262CrossRefPubMed

Wiggins CL, Harlan LC, Nelson HE, Stevens JL, Willman CL, Libby EN, Hromas RA (2010) Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med 123 (8):764.e761–769. doi:10.1016/j.amjmed.2010.03.018

Medicine Matters Oncology

Abstract